Core Viewpoint - Sunrun Inc. (RUN) is expected to report its second-quarter 2025 results on August 6, with a focus on sales growth driven by solar demand and challenges from increased costs [1][4]. Group 1: Financial Performance Expectations - The Zacks Consensus Estimate for Sunrun's Q2 sales is $557.2 million, reflecting a 6.4% increase from the previous year [4][9]. - The earnings estimate for the upcoming quarter is a loss of 18 cents per share, a decline from earnings of 55 cents per share reported in the same quarter last year [4][9]. Group 2: Factors Influencing Results - Strong sales volume for solar energy systems and products, along with a growing customer base and increased storage attachment rates, are expected to positively impact revenues [2]. - However, rising expenses due to higher battery hardware and installation labor costs from increased storage attachment rates may negatively affect overall earnings [3]. Group 3: Earnings Prediction Insights - The current Earnings ESP for Sunrun is -47.26%, indicating a low probability of an earnings beat this quarter [5]. - Sunrun holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook compared to other stocks in the sector [6].

Core Viewpoint - Aflac Incorporated (AFL) is expected to report a decline in both earnings and revenues for the second quarter of 2025, with earnings estimated at $1.71 per share and revenues at $4.43 billion, reflecting year-over-year decreases [1][7]. Financial Estimates - The second-quarter earnings estimate has decreased by 2 cents over the past 60 days, indicating a year-over-year decline of 6.6% [2]. - The Zacks Consensus Estimate for total revenues in the second quarter suggests a year-over-year decrease of 13.7% [2]. - For the full year 2025, the revenue estimate is $17.68 billion, implying a 0.9% decline year over year, while the EPS estimate is $6.75, indicating a 6.4% year-over-year decline [3]. Earnings Performance - Aflac has beaten earnings estimates in two of the past four quarters and missed twice, with an average surprise of 9.3% [3]. - The current Earnings ESP is -1.25%, and the Zacks Rank is 2 (Buy), suggesting uncertainty regarding an earnings beat this quarter [4]. Factors Influencing Q2 Results - Expected premium growth may be offset by lower earnings from Japan and weaker investment income [7]. - The consensus estimate for total net earned premiums indicates a 3.4% year-over-year increase, while the Aflac U.S. unit is expected to see a 3.3% increase in adjusted revenues, contrasting with a 2.6% decline in the Aflac Japan unit [8]. - Net investment income is projected to decline by 17.2% year over year [9]. - The total benefit to premium ratio for Aflac U.S. is expected to rise to 47.8 from 46.7 a year ago, while Aflac Japan's ratio is expected to decrease to 65.3 from 66.9 [9]. - Pre-tax adjusted earnings from Aflac U.S. are estimated to fall by 8.1%, and Aflac Japan is likely to see a 13.2% decline [9][10]. Peer Performance - Marsh & McLennan reported adjusted earnings of $2.72 per share, surpassing estimates by 2.3% due to strong growth in Risk and Insurance Services [11]. - AON reported adjusted earnings of $3.49 per share, beating estimates by 2.7%, benefiting from new business growth and solid retention rates [12]. - AMERISAFE reported adjusted earnings of 53 cents per share, missing estimates by 3.6%, affected by a drop in net investment income and elevated expenses [13].

Core Viewpoint - Axon Enterprise, Inc. is expected to report strong second-quarter 2025 results, with earnings projected at $1.54 per share and revenues at $643 million, reflecting significant year-over-year growth [2][8]. Financial Performance - The earnings estimates for the second quarter have increased by 4.8% over the past 60 days, indicating a 28.3% increase from the previous year [2]. - The Zacks Consensus Estimate for quarterly revenues suggests a year-over-year growth of 27.6% [2]. - Axon has a history of exceeding earnings estimates, with an average surprise of 19.8% over the last four quarters [3]. Segment Performance - The Connected Devices segment is anticipated to generate revenues of $364 million, a 23.4% increase from the previous year, driven by strong demand for TASER devices and the new Axon Body 4 camera [6][8]. - The Software & Services segment is expected to see revenues rise by 35.4% to $283 million, supported by user growth and enhanced cloud offerings [9][8]. Strategic Initiatives - The company is focused on acquisitions and partnerships to enhance its product offerings, including the acquisition of Dedrone for airspace security and a partnership with Skydio for drone solutions [10]. - The increase in the number of users on the Axon network and benefits from recent acquisitions are likely to contribute positively to future performance [19]. Market Position - Axon shares have increased by 20.3% over the past three months, outperforming the S&P 500's 12.2% increase [12]. - The company's current valuation is high, with a forward P/E ratio of 103.48X, significantly above the industry average of 52.76X, which may pose risks if market sentiment changes [15][16]. Investment Outlook - The company is well-positioned for sustained growth due to its diversified product portfolio, strategic collaborations, and strong market demand [18][20]. - Positive analyst sentiment and robust growth prospects make Axon an attractive addition to investment portfolios [20].

Core Insights - TransDigm Group Incorporated (TDG) is expected to report its third-quarter fiscal 2025 results on August 5, with a trailing four-quarter average earnings surprise of 5.13% [1][6] - The growth in commercial air travel and strong defense sales are anticipated to positively impact the quarterly performance [1] Segment Performance - The Power & Control segment is projected to generate revenues of $1.20 billion, reflecting a 17.1% increase from the previous year, driven by strong commercial aftermarket sales and improved defense spending [2][3] - The Airframe segment is expected to report revenues of $1.06 billion, indicating a 9% growth year-over-year, supported by rising demand for defense products and increased air travel [4][8] Overall Financial Expectations - The overall sales for TDG in the fiscal third quarter are estimated at $2.30 billion, representing a 12.2% improvement compared to the prior year [5][8] - Earnings per share are projected to be $9.78, which is an 8.7% increase from the same quarter last year, aided by strong revenue growth and cost reduction initiatives [6] Earnings Prediction - The Zacks model indicates a likely earnings beat for TDG, with an Earnings ESP of +0.40% and a Zacks Rank of 2 (Buy) [7][9]

Core Viewpoint - Allison Transmission Holdings, Inc. is expected to report second-quarter 2025 results on August 4, with sales and earnings estimates of $794.43 million and $2.20 per share respectively [1][8] Financial Performance - The earnings projection indicates a year-over-year increase of 3.29%, while the revenue estimate suggests a decline of 2.64% compared to the previous year [2] - In the first quarter of 2025, Allison reported adjusted earnings of $2.23 per share, exceeding the Zacks Consensus Estimate of $1.97, and reflecting a 17% year-over-year increase. However, quarterly revenues of $766 million fell 3% from the previous year and missed the consensus estimate of $775 million [2] Market Demand and Outlook - Strong demand for Class 8 vocational vehicles in the North America On-Highway market is driving revenue growth, with expectations to continue this trend into 2025. The company anticipates adjusted EBITDA between $1.17 billion and $1.23 billion for 2025, an increase from $1.165 billion in 2024, and net income projected between $735 million and $785 million, up from $731 million in 2024 [3] R&D and Cost Pressures - The company's electrified propulsion initiatives are expected to increase spending levels, impacting cash flows. R&D costs rose approximately 3% year-over-year in 2024 due to higher spending on product initiatives, and further increases in R&D expenses are anticipated in 2025 [4] Earnings Prediction - The current model does not predict an earnings beat for Allison in the upcoming quarter, as it lacks the necessary combination of positive Earnings ESP and a favorable Zacks Rank [5] - Allison has an Earnings ESP of -0.41% and currently holds a Zacks Rank of 3 [6]

Core Insights - Cboe Global Markets, Inc. (CBOE) is anticipated to show improvements in both revenue and earnings for Q2 2025, with revenue expected at $572.24 million, reflecting an 11.3% year-over-year growth [2] - The earnings consensus estimate is $2.42 per share, indicating a 12.5% increase from the previous year, with a slight upward revision of 0.8% in the last 30 days [3] Revenue and Earnings Estimates - The Zacks Consensus Estimate for CBOE's second-quarter revenues is $572.24 million, which is an 11.3% increase from the prior year [2] - The earnings estimate for the quarter is $2.42 per share, representing a year-over-year increase of 12.5% [3] Earnings Prediction Model - The earnings prediction model indicates a likely earnings beat for Cboe Global, supported by a positive Earnings ESP of +0.66% and a Zacks Rank of 3 (Hold) [4][5] Factors Influencing Q2 Results - Growth in index options, higher transaction and clearing fees, and increased access and capacity fees are expected to positively impact CBOE's Q2 performance [6] - Increased revenues from cash and spot markets, as well as derivatives markets, are anticipated due to higher transaction volumes on Cboe exchanges [7] Fee Structure and Revenue Breakdown - The company expects higher revenues from proprietary market data fees, with estimates of $81.1 million for market data revenues and $96.6 million for access and capacity fees [9] - Increased transaction and clearing fees are projected to benefit both cash and spot markets as well as the derivatives business [8] Product Performance - Cboe Global is expected to benefit from strong performance in proprietary products, including VIX futures and SPX options, along with growth in multi-listed options trading [12] - Continued share buybacks are anticipated to support the bottom line for the quarter [12]

Core Insights - Mastercard is expected to report Q2 2025 earnings on July 31, 2025, with an estimated EPS of $4.05 and revenues of $7.99 billion, reflecting year-over-year increases of 12.8% and 14.7% respectively [1][2][8] Financial Performance - The full-year 2025 revenue estimate for Mastercard is $31.96 billion, indicating a 13.5% year-over-year growth, while the EPS estimate is $16.04, suggesting a 9.9% increase [3] - Mastercard has consistently surpassed earnings estimates, achieving an average surprise of 3.7% over the last four quarters [4] Earnings Predictions - The company is projected to experience growth in switched transactions, cross-border volumes, and value-added services, contributing to its Q2 performance [8] - The Gross Dollar Volume (GDV) is expected to rise by 7.4% year-over-year, with domestic operations increasing by nearly 7% and international operations by 6% [9] - Switched transactions are anticipated to grow by 10.4% year-over-year, driven by consumer spending and contactless payment initiatives [10] - Cross-border volumes are expected to increase by 17.1%, with domestic assessments and transaction processing assessments projected to rise by 10.2% and 13.5% respectively [11] Cost and Margin Considerations - Adjusted operating expenses are expected to rise nearly 16% year-over-year, influenced by higher general and administrative costs as well as advertising and marketing expenses [14] - Payments network rebates and incentives are projected to increase by 12.6% year-over-year, which may impact margins despite strong revenue growth [14][13] Stock Performance and Valuation - Mastercard's stock has gained 8% year-to-date, outperforming the industry average of 4.7% [15] - The current forward P/E ratio for Mastercard is 32.33, above its five-year median of 31.74 and the industry average of 22.19 [17] - Competitors Visa and American Express are trading at lower forward P/E ratios of 28.31 and 18.85 respectively, indicating better value [19] Strategic Outlook - Mastercard is enhancing its competitive edge through digital capabilities, merchant engagement, and customer experience improvements [20] - The company is focusing on tokenized transactions and stablecoin infrastructure as part of its innovative strategy [20] - Value-added services are expected to remain a significant growth driver, supported by robust cash flows for dividends and strategic investments [20]

Core Viewpoint - Linde plc is expected to report its second-quarter 2025 results on August 1, with earnings per share estimated at $4.03 and revenues at $8.35 billion, reflecting a year-over-year improvement in earnings and revenues [1][3][9]. Group 1: Q1 Performance and Expectations - In the previous quarter, Linde's earnings were $3.95 per share, surpassing the Zacks Consensus Estimate of $3.93, driven by higher pricing and increased volumes from the Americas segment [2]. - The Zacks Consensus Estimate for second-quarter earnings per share is $4.03, indicating a 4.68% improvement from the prior-year quarter [2]. - The expected revenue for the second quarter is $8.35 billion, which represents a year-over-year increase of 1.04% [3]. Group 2: Market Position and Performance Factors - Linde is a global leader in industrial gas production, serving various end markets including healthcare, manufacturing, and chemicals & refining [4]. - The company is anticipated to maintain stable performance due to long-term contracts with major on-site clients and operations in resilient end markets such as healthcare and food and beverages [5]. - However, challenges may arise from tariffs and changes in trade policies, which could slow down industrial activity globally, particularly affecting demand in markets like China and Europe [6]. Group 3: Segment Performance Estimates - The Zacks Consensus Estimate for operating profit in the Americas segment is $1.19 billion, an increase from $1.16 billion in the second quarter of 2024 [7]. - The operating profit estimate for the Engineering business unit is $100 million, up from $96 million a year ago [7]. - These factors are expected to influence demand and pricing dynamics, potentially impacting Linde's quarterly performance [7].

Core Viewpoint - Vertex Pharmaceuticals (VRTX) is expected to exceed expectations in its second-quarter 2025 results, with projected revenues of $2.89 billion and earnings of $4.24 per share [1][2]. Group 1: Sales Performance - Vertex's cystic fibrosis (CF) franchise sales are growing, primarily driven by increased sales of its CF medicine, Trikafta/Kaftrio, particularly in younger age groups [3][7]. - Strong demand for Trikafta/Kaftrio in the U.S. is anticipated to drive revenues, although international sales faced challenges due to illegal copy products in Russia [4][5]. - Trikafta/Kaftrio sales estimates are $2.56 billion according to Zacks Consensus and $2.50 billion based on internal models, with potential sales erosion from other CF drugs [5][9]. Group 2: New Product Developments - Vertex's new gene therapy, Casgevy, approved for sickle cell disease and beta-thalassemia, recorded $14.2 million in sales in Q1 2025, with a sequential increase of 77.5% expected in Q2 [8][9]. - The fifth CF medicine, Alyftrek, generated $53.9 million in sales in Q1 2025, with steady uptake noted, although the switch from Trikafta to Alyftrek has been slower than anticipated [10][11]. - Journavx, a non-opioid pain medicine, was recently approved but had insignificant sales in the last quarter, with expectations for improvement in the second half of the year [12]. Group 3: Earnings Expectations - Vertex's earnings surprise history shows a mixed performance, with one earnings beat in the last four quarters and an average negative surprise of 2.39% [14]. - The company's Earnings ESP is +1.82%, indicating a potential earnings beat, supported by a Zacks Rank of 3 [15][16].

Core Viewpoint - Moderna (MRNA) is expected to exceed earnings expectations for Q2 2025, with a prior earnings surprise of 13.70% in the last quarter. The consensus estimates for sales and earnings are $127 million and a loss of $2.99 per share, respectively [1][9]. Factors Shaping MRNA's Upcoming Results - A significant portion of Moderna's revenue is anticipated to come from the COVID-19 vaccine, Spikevax, with estimated sales of $59 million, reflecting a notable decline from the previous year due to reduced demand [2]. - Minimal sales are expected from the RSV vaccine, mResvia, with projections of only $2 million, which is considerably lower than competing products from GSK and Pfizer. This is attributed to the later approval and recommendation of the vaccine [3]. Regulatory Developments - The FDA has expanded the label for mResvia to include high-risk adults aged 18-59, and the CDC has updated its recommendations for RSV vaccines to include high-risk adults aged 50-59. Investors are looking for updates on marketing strategies for both vaccines [4]. - A regulatory filing is under FDA review to update Spikevax for the LP.8.1 variant for the 2025-26 vaccination season, with a similar filing also under review by the EMA. Investors are keen on updates regarding these regulatory processes [5]. Pipeline Candidates - Moderna is advancing several late-stage pipeline candidates, including the influenza vaccine candidate mRNA-1010, which has shown superior efficacy compared to an approved flu shot. This supports potential approval for a standalone flu shot and strengthens the case for the combination vaccine mRNA-1083 [6]. - An important candidate is intismeran autogene, a personalized cancer therapy developed in collaboration with Merck, currently evaluated in pivotal phase III studies for various cancer indications. Investors are interested in updates on this therapy's progress [7]. Earnings Surprise History - Moderna has consistently beaten earnings estimates over the past four quarters, achieving an average surprise of 31.60% [8]. Market Performance - Year to date, Moderna's shares have declined by 18%, contrasting with a 2% growth in the industry [10].